Usage Examples
- The MABEL was set from receptor occupancy in human PBMCs, not from the cynomolgus NOAEL.
- Our protocol justifies the starting dose against MABEL, PAD and NOAEL, because the target biology does not translate cleanly from monkey.
- Sentinel dosing stays in place through every cohort, regardless of how far the dose sits below the MABEL.
What is Minimum Anticipated Biological Effect Level (MABEL)?
Minimum Anticipated Biological Effect Level (MABEL) is the human exposure predicted to produce the lowest biologically observable effect, calculated from pharmacology rather than toxicology, and used by EMA as one of three permitted anchors for a first-in-human starting dose.
MABEL exists because a toxicology-anchored dose can miss the risk that actually matters. A dose sitting safely below the animal NOAEL can still be pharmacologically potent in humans when target biology differs across species. EMA published the original first-in-human guideline in 2007 and issued Revision 1, EMEA/CHMP/SWP/28367/07 Rev. 1, adopted 20 July 2017 and in effect from 1 February 2018.
MABEL covers the human exposure at which biological effect is first anticipated, built from nonclinical pharmacodynamic exposures, ex vivo and in vitro human tissue data, and receptor occupancy in target cells. MABEL is not the starting dose itself and not a toxicology endpoint. EMA's own text spells it "minimal anticipated biological effect level"; the minimum and minimal spellings describe the same level.
MABEL is applied through the protocol, not through a modelling report that stays in the sponsor's files. The methods and calculations behind the dose and exposure estimates, including PK/PD and PBPK modelling, belong in the protocol and may be summarised in the Investigator's Brochure. Safety factors applied on top of MABEL must account for uncertainty in the MABEL estimate itself.
Not to be confused with
- NOAEL
- NOAEL is the highest nonclinical dose producing no adverse effect, a toxicology endpoint. MABEL is a pharmacology endpoint estimating where effect begins. EMA treats them as alternative anchors chosen by uncertainty level, not as one superseding the other.
- PAD (pharmacologically active dose)
- PAD is the dose expected to produce a meaningful pharmacological effect. MABEL is the level at which any biological effect is first anticipated. EMA requires the healthy-volunteer starting exposure to sit below the PAD.
- Sentinel dosing
- sentinel dosing is a trial-conduct precaution: dose one subject, observe, then dose the rest of the cohort. MABEL is a dose-estimation method. EMA expects sentinel dosing regardless of which anchor set the starting dose.
- MTD (maximum tolerated dose)
- MTD is discovered by escalating until toxicity appears. MABEL is predicted before any human is dosed. EMA states that an MTD design is inappropriate for healthy volunteers.
MABEL obligations sit inside EMA's first-in-human guideline rather than in a standalone rule.
What you must do
- 1Determine the MABEL in humans from exposures showing pharmacodynamic effects in nonclinical pharmacology studies, including ex vivo and in vitro studies in human tissues where feasibleEMEA/CHMP/SWP/28367/07 Rev. 1 §7.2
- 2Base the MABEL, PAD and ATD calculation on target binding and receptor occupancy in target cells from humans and the relevant animal species, integrating all relevant data in a modelling approachEMEA/CHMP/SWP/28367/07 Rev. 1 §7.2
- 3Set the healthy-volunteer starting exposure below the PAD, and relate it to the MABEL, PAD or NOAEL according to the level of residual nonclinical uncertaintyEMEA/CHMP/SWP/28367/07 Rev. 1 §7.2
- 4Document the dose and exposure calculation methods, including PK/PD and PBPK modelling, in the clinical trial protocolEMEA/CHMP/SWP/28367/07 Rev. 1 §7.1
- 5Dose one sentinel subject ahead of the remainder of each cohort, or give a clear scientific rationale on a risk-proportionate basis for not doing soEMEA/CHMP/SWP/28367/07 Rev. 1 §8.2.6
- 6Consider the full nonclinical package, including pharmacological dose response, the pharmacological and toxicological profile, and pharmacokinetics, when setting the recommended human starting doseICH M3(R2) §6
Common mistakes
Presenting MABEL as the only justification and dropping NOAEL
Revision 1 ties the starting dose to MABEL, PAD or NOAEL according to how much uncertainty remains. A submission that shows only a MABEL derivation withholds the comparison the assessor needs to judge whether the right anchor was chosen.
Calculating MABEL from animal pharmacology alone
The guideline expects ex vivo and in vitro human tissue data where feasible, plus receptor occupancy in target cells from both humans and the relevant animal species. An animal-only MABEL reproduces the species-sensitivity gap the method exists to close.
Keeping the modelling outside the protocol
Sponsors routinely derive the number in an internal PK/PD or PBPK report and put only the result in the protocol. EMA requires the methods and calculations in the protocol; summarising them in the Investigator's Brochure is permitted as an addition, not as a replacement.
When This Matters
- The MABEL was set from receptor occupancy in human PBMCs, not from the cynomolgus NOAEL.
- Our protocol justifies the starting dose against MABEL, PAD and NOAEL, because the target biology does not translate cleanly from monkey.
- Sentinel dosing stays in place through every cohort, regardless of how far the dose sits below the MABEL.
Frequently Asked Questions
No. EMA's first-in-human guideline states that the starting dose should be related to the MABEL, PAD or NOAEL, depending on the level of uncertainty about the human relevance of nonclinical findings and how well the intended target is understood. MABEL is an alternative anchor, not a mandatory substitute.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Clinical Workflows
Track clinical trial regulations across global markets
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Related Regulatory Intelligence
Related Actions
Sources & References
- EMA - Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products
- EMEA/CHMP/SWP/28367/07 Rev. 1 - full guideline text (PDF)
- ICH M3(R2) - Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
